Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azathioprine for multiple sclerosis.

I Casetta1, G Iuliano, G Filippini

  • 1Universita degli Studi di Ferrara, Clinica Neurologica, Corso Giovecca, 203, Ferrara, Italy, 44100. cti@dns.unife.it

The Cochrane Database of Systematic Reviews
|October 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transgenerational plasticity responses of larvae of Sydney rock oysters (Saccostrea glomerata) to ocean warming.

Marine pollution bulletin·2025
Same author

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Journal of medical economics·2023
Same author

Outcomes with Endovascular Treatment of Patients with M2 Segment MCA Occlusion in the Late Time Window.

AJNR. American journal of neuroradiology·2023
Same author

Wireless phone use in childhood and adolescence and neuroepithelial brain tumours: Results from the international MOBI-Kids study.

Environment international·2022
Same author

Use of benzodiazepines and cognitive performance in primary care patients with first cognitive complaints.

International psychogeriatrics·2017
Same author

Role of anticholinergic burden in primary care patients with first cognitive complaints.

European journal of neurology·2017
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Azathioprine effectively reduces relapses and disability progression in multiple sclerosis (MS) patients. While side effects are manageable, long-term use requires monitoring for potential malignancy risks.

Area of Science:

  • Immunology and Neurology
  • Pharmacological Efficacy in Autoimmune Diseases

Background:

  • Azathioprine is a common, cost-effective immunosuppressant for multiple sclerosis (MS).
  • Concerns regarding malignancy risk have tempered its widespread use.
  • This review assesses the benefit-risk balance of azathioprine in MS management.

Purpose of the Study:

  • To compare azathioprine against placebo in MS patients.
  • To evaluate azathioprine's impact on disability progression and relapse rates.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) of at least one-year duration.
  • Searched multiple databases including MEDLINE, EMBASE, Cochrane Library, DARE.
  • Included cohort and case-control studies for adverse effect assessment.

Related Experiment Videos

Main Results:

  • Azathioprine significantly reduced relapse rates at one, two, and three years.
  • A significant benefit in delaying disability progression was observed at three years.
  • Manageable adverse effects (gastrointestinal, bone marrow, hepatic) occurred; malignancy risk was not increased in trials, but a potential long-term risk exists with cumulative doses >600g.

Conclusions:

  • Azathioprine is suitable for relapsing MS patients requiring maintenance therapy.
  • Limit cumulative doses to 600g to mitigate potential malignancy risk.
  • Azathioprine presents a viable alternative to interferon beta, warranting direct comparative trials.